Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2023-03-14 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
关于健民药业集团股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告(众环专字(2023)0100112号)
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by Zhongshenzhonghuan Certified Public Accountants LLP regarding the non-operating fund occupation and other related party fund transactions of Jianmin Pharmaceutical Group Co., Ltd. for the year ended December 31, 2022. It references the audit of the company's 2022 consolidated financial statements and provides an audit opinion on a specific summary table related to non-operating fund occupation and related party transactions. The document includes detailed financial data and audit procedures, indicating it is a standalone audit report rather than a full annual report or a brief announcement. The presence of an audit opinion and detailed financial review aligns with the definition of an Audit Report / Information (AR). The document length (8718 characters) and content confirm it is not a mere announcement or certification but a substantive audit report.
2023-03-14 Chinese
健民集团监事会关于2022年年报的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's audit opinion on the company's 2022 annual report. It references the annual report but does not contain the full report or detailed financial data itself. The document is short (321 characters) and serves as an audit opinion or certification related to the annual report. According to the rules, such standalone audit opinions or certifications are classified as Audit Report / Information (AR). FY 2022
2023-03-14 Chinese
健民集团第十届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board meeting of the company, detailing votes on various agenda items including the 2022 Supervisory Board work report, the 2022 annual report, profit distribution plan, financial budget report, and internal control evaluation report. It is a formal announcement of meeting decisions rather than the full reports themselves. The document length is short (1006 characters) and it references that the full reports are disclosed elsewhere (e.g., on the stock exchange website). This fits the pattern of a Regulatory Filing (RNS) as it is a formal regulatory announcement of meeting resolutions and report approvals, not the reports themselves or their presentations. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-14 Chinese
健民集团审计委员会2022年度述职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022 Audit Committee Work Report" of the company, detailing the audit committee's activities, meetings, oversight of the annual report audit, internal controls, and related audit matters for the fiscal year 2022. It references the audit process, interaction with the external auditor, and internal audit work, but it is not the full annual report itself. The document is a detailed report from the audit committee on their duties and findings related to the audit of the annual report, which fits the definition of an Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content about audit activities, not merely an announcement or certification, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the best classification is AR with high confidence. FY 2022
2023-03-14 Chinese
健民集团2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 年年度报告摘要" (2022 Annual Report Summary) of 健民药业集团股份有限公司. It contains detailed financial data such as revenue, profit, business segments, product lines, R&D activities, production, marketing, and policy environment analysis for the fiscal year 2022. The length is substantial (15,000 characters), and it includes comprehensive financial and operational information typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-03-14 Chinese
健民集团关于2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of the company, including details on cash dividends per share, total profit distribution amount, and the need for shareholder approval at the upcoming general meeting. It includes references to the audit report but does not contain the full audit report or detailed financial statements. The document is relatively short (1980 characters) and primarily serves to inform shareholders about the dividend proposal and related corporate governance procedures. This fits the definition of a Notice of Dividend Amount (DIV) rather than a full Annual Report or Audit Report. Therefore, the appropriate classification is DIV.
2023-03-14 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.